Faculty, Staff and Student Publications

Language

English

Publication Date

1-1-2026

Journal

Advanced Science

DOI

10.1002/advs.202503866

PMID

41236163

PMCID

PMC12806547

PubMedCentral® Posted Date

11-14-2025

PubMedCentral® Full Text Version

Post-print

Abstract

Mutations in isocitrate dehydrogenase (IDH) genes sensitize gliomas to PARP inhibition (PARPi) by inducing epigenetic reprogramming of DNA damage repair circuits. However, tumors treated with PARPi eventually relapse despite initial responsiveness. In this study, it is demonstrated that the anti-angiogenic agent lenvatinib synergizes effectively with PARPi, resulting in substantial tumor regression and significantly extended survival. Genomic analysis of tumors reveals that PARPi induces widespread transcriptomic changes that are predominantly pro-inflammatory, thereby promoting tumor angiogenesis. Prickle4, a planar cell polarity protein, is identified as a critical mediator of PARPi-induced neovascularization. Targeting Prickle4 effectively overcomes PARPi resistance in these tumors. Collectively, these findings identified the Prickle4-mediated microenvironmental remodeling as the key resistance mechanism to PARPi, and support the therapeutic promise of multimodal therapy combining PARPi with anti-angiogenic agents for glioma treatment.

Keywords

Glioma, Humans, Tumor Microenvironment, Poly(ADP-ribose) Polymerase Inhibitors, Animals, Isocitrate Dehydrogenase, Mice, Drug Resistance, Neoplasm, Mutation, Brain Neoplasms, Cell Line, Tumor, Neovascularization, Pathologic, angiogenesis, glioma, IDH, PARP

Published Open-Access

yes

Download

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.